You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,231,885


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,231,885 protect, and when does it expire?

Patent 8,231,885 protects MIRVASO and is included in one NDA.

This patent has eighty-seven patent family members in twenty-five countries.

Summary for Patent: 8,231,885
Patent landscape, scope, and claims:
Title:Compounds, formulations, and methods for ameliorating telangiectasis
Abstract: Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an .alpha.-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.
Inventor(s): DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee: Galderma Laboratories Inc. (Fort Worth, TX)
Application Number:12/544,663
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,231,885
Patent Claim Types:
see list of patent claims
Composition; Delivery; Formulation;

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,231,885

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Galderma Labs Lp MIRVASO brimonidine tartrate GEL;TOPICAL 204708-001 Aug 23, 2013 AB RX Yes Yes 8,231,885 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,231,885

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 1631293 ⤷  Subscribe CR 2014 00031 Denmark ⤷  Subscribe
European Patent Office 1631293 ⤷  Subscribe C300683 Netherlands ⤷  Subscribe
European Patent Office 1631293 ⤷  Subscribe 1490049-2 Sweden ⤷  Subscribe
European Patent Office 1631293 ⤷  Subscribe C20140022 00150 Estonia ⤷  Subscribe
European Patent Office 1631293 ⤷  Subscribe 92462 Luxembourg ⤷  Subscribe
European Patent Office 1631293 ⤷  Subscribe 191 5019-2014 Slovakia ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.